BridgeBio Pharma, Inc.

For the period ended Sep 30, 2026. Filed Oct 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 29, 2026

BBIO$77.93+4.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

September 30,2026 · December 31,2025
	(Unaudited)	(1)
Assets
Current assets:
Cash and cash equivalents	$1,533,363		$570,119
Marketable securities	5,492		17,363
Accounts receivable, net	375,089		139,444
Inventories	59,718		26,753
Prepaid expenses and other current assets	70,944		44,070
Total current assets	2,044,606		797,749
Equity method investments	47,783		79,972
Property and equipment, net	5,042		5,366
Operating lease right-of-use assets	15,746		8,149
Intangible assets, net	25,923		28,077
Other assets	22,686		16,712
Total assets	$2,161,786		$936,025
Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit
Current liabilities:
Accounts payable	$88,258		$36,228
Accrued compensation and benefits	66,686		76,703
Accrued research and development liabilities	55,018		41,436
Operating lease liabilities, current portion	1,987		6,192
Deferred revenue, current portion	4,744		7,190
2027 Notes, net	548,430		—
Other current liabilities (2)	212,114		120,222
Total current liabilities	977,237		287,971
2027 Notes, net	—		547,015
2029 Notes, net	742,437		740,890
2031 Notes, net	566,013		564,565
2033 Notes, net	620,533		—
Deferred royalty obligations, net (3)	884,053		855,030
Operating lease liabilities, net of current portion	14,645		3,811
Deferred revenue, net of current portion	8,968		13,080
Other long-term liabilities	1,405		244
Total liabilities	3,815,291		3,012,606
Commitments and contingencies (Note 7)
Redeemable convertible noncontrolling interests	(1,363)		(570)
Stockholders’ deficit:
Undesignated preferred stock, $0.001 par value; 24,066,100 shares authorized and no shares issued and outstanding as of September 30, 2026; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025	—		—
Series A preferred stock, $0.001 par value; 933,900 shares authorized, issued, and outstanding as of September 30, 2026 (aggregate liquidation preference of $1,134,359 as of September 30, 2026)	942,478		—
Common stock, $0.001 par value; 500,000,000 shares authorized; 207,300,005 shares issued and 196,004,842 shares outstanding as of September 30, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025	207		202
Treasury stock, at cost; 11,295,163 shares as of September 30, 2026; 7,597,172 shares as of December 31, 2025	(580,775)		(323,276)
Additional paid-in capital	2,170,006		2,057,646
Accumulated other comprehensive income (loss)	(95)		12
Accumulated deficit	(4,194,163)		(3,821,194)
Total BridgeBio stockholders’ deficit	(1,662,342)		(2,086,610)
Noncontrolling interests	10,200		10,599
Total stockholders’ deficit	(1,652,142)		(2,076,011)
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit	$2,161,786		$936,025

(1)The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.

(2)Including related party amounts ofnil and $2,003 as of September 30, 2026 and December 31, 2025, respectively (as described in Note 9).

(3)Including related party amounts ofnil and $204,650 as of September 30, 2026 and December 31, 2025, respectively (as described in Note 9).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.